Reid Huber Ph.D Overview
- Firm
- Third Rock Ventu...
- Primary Position
-
Partner
- Primary Industry
-
Healthcare
- Active Board Seats
-
6
- Med. Deal Size
-
- Med. Valuation
-
Reid Huber Ph.D General Information
Biography
Dr. Reid Huber serves as Partner at Third Rock Ventures. Mr. Huber serves as a Board Member at Rapport Therapeutics. He served as a Board Member at Cargo Therapeutics. He serves as a Board Member at Tango Therapeutics. He also serves as a Board Member at Bellicum Pharmaceuticals, Terremoto Biosciences, MoMa Therapeutics, Asher Biotherapeutics. He serves as a Board Observer at insitro. He serves as an Advisory Board Member at Mass General Brigham Innovation. He brings over 20 years of operating experience in the biotechnology industry to focus on the formation, development, and strategy of our portfolio companies. He was a member of the founding scientific team at Incyte in 2002 and most recently served as the company's Executive Vice President and Chief Scientific Officer. He serves as an Advisory Board Member at Partners HealthCare Innovation. He has held roles of increasing responsibility in both drug discovery and clinical development at Incyte, most recently as Executive Director of clinical Development. Prior to Incyte, he held positions of increasing responsibility at Dupont Pharmaceuticals and Bristol-Myers Squibb. He conducted his postdoctoral training at the National Institutes of Health. Dr. Huber held intramural pre-doctoral and post-doctoral fellowships at the National Institutes of Health from 1997-1998. He is particularly excited about initiatives at the firm that combine deep understandings of disease genetics, data science, and translational medicine. He is consistently impressed with his colleague's focus on leveraging emerging areas of high-potential science to create breakthrough medicines for patients. Dr. Huber received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University.
Contact Information
Address
- 201 Brookline Avenue
- Suite 1401
- Boston, MA 02215
- United States
Reid Huber Ph.D Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Third Rock Ventures | Investor | Partner | Boston, MA | Venture Capital |
Reid Huber Ph.D Board Seats (6)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
AsherBio | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | South San Francisco, CA | |
Cargo Therapeutics | Drug Discovery | Publicly Held | Formerly VC-backed | San Carlos, CA | |
insitro | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | South San Francisco, CA | |
MoMa Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Cambridge, MA | |
Rapport Therapeutics | Drug Discovery | Publicly Held | Formerly VC-backed | Boston, MA |
Reid Huber Ph.D Lead Partner on Deals (10)
Reid Huber Ph.D has been the lead partner on 10 deals. Their latest deal was with Synnovation Therapeutics, a drug discovery company. The deal was made for on 24-Jan-2024.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Synnovation Therapeutics | 24-Jan-2024 | Early Stage VC (Series A) | Completed | Drug Discovery | Wilmington, DE | |
Tango Therapeutics | 11-Aug-2023 | Completed | Drug Discovery | Boston, MA | ||
Rapport Therapeutics | 07-Aug-2023 | Completed | Drug Discovery | Boston, MA | ||
Rapport Therapeutics | 07-Mar-2023 | Completed | Drug Discovery | Boston, MA | ||
Cargo Therapeutics | 09-Feb-2023 | Completed | Drug Discovery | San Carlos, CA | ||
Terremoto Biosciences | 25-May-2022 | Completed | Drug Delivery | San Francisco, CA | ||
MoMa Therapeutics | 09-May-2022 | Completed | Drug Discovery | Cambridge, MA | ||
MoMa Therapeutics | 15-Apr-2020 | Completed | Drug Discovery | Cambridge, MA | ||
Syros Pharmaceuticals | 08-Jan-2018 | PIPE | Completed | Drug Discovery | Cambridge, MA | |
Calithera | 31-Mar-2017 | PIPE | Completed | Biotechnology | South San Francisco, CA |
Reid Huber Ph.D Network (187)
Board Members (66)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Mace Rothenberg MD | Tango Therapeutics | Self | Boston, MA | |
Abraham Ceesay | Rapport Therapeutics | Rapport Therapeutics | Boston, MA | |
Bellicum Pharmaceuticals | Self | Houston, TX | ||
AsherBio | AsherBio | South San Francisco, CA | ||
insitro | Self | South San Francisco, CA |
Portfolio Executives (105)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Wenqing Yao Ph.D | Synnovation Therapeutics | Co-Founder, Chief Executive Officer & Board Member | 24-Jan-2024 | Wilmington, DE |
Liangxing Wu Ph.D | Synnovation Therapeutics | Co-Founder, Senior Vice President of Drug Discovery & Board Member | 24-Jan-2024 | Wilmington, DE |
Tango Therapeutics | Co-Founder | 11-Aug-2023 | Boston, MA | |
Tango Therapeutics | Chief Development Operations Office | 11-Aug-2023 | Boston, MA | |
Tango Therapeutics | Executive | 11-Aug-2023 | Boston, MA |
Fund Team Members (16)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Charles Homcy MD | Third Rock Ventures | Third Rock Ventures IV | Boston, MA |
Charles Homcy MD | Third Rock Ventures | Third Rock Ventures V | Boston, MA |
Third Rock Ventures | Boston, MA | ||
Third Rock Ventures | Boston, MA | ||
Third Rock Ventures | Boston, MA |
Reid Huber Ph.D Affiliated Funds (2)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Third Rock Ventures IV | Third Rock Ventures | Venture - General | Closed | 2016 | ||||
Third Rock Ventures V | Third Rock Ventures | Venture - General | Closed | 2020 |
Reid Huber Ph.D Advisory Roles (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Mass General Brigham Innovation | Investor | Advisory Board Member | Cambridge, MA | Corporate Venture Capital |
Reid Huber Ph.D FAQs
-
Who is Reid Huber Ph.D?
Dr. Reid Huber serves as Partner at Third Rock Ventures.
-
How much does Reid Huber Ph.D typically invest?
Reid Huber Ph.D's median deal size is
. -
What is Reid Huber Ph.D’s main position?
Reid Huber Ph.D’s primary position is Partner.
-
What are the contact details for Reid Huber Ph.D?
Reid Huber Ph.D’s email address is rh
and his phone number is +1 (617) . -
How many active board seats does Reid Huber Ph.D hold?
Reid Huber Ph.D holds 6 board seats including AsherBio, Cargo Therapeutics, insitro, MoMa Therapeutics, and Rapport Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »